Tool: DupCheckTool: DupCheck

www.DupCheck.org is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.


Project FlyerProject Flyer


Click here to download 
the NEWMEDS project flyer! 


ConsortiumConsortium
consortium teaser

QuicklinksQuicklinks
Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms




  Members Area
Username:
Password:



EU
IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

logo Karoliska Institutet

Karolinska  Institutet
Nobels väg 5
17177
Stockholm
Sweden

Karolinska www. ki.se



Participant's Lead


Prof. Christer Halldin Prof. Christer Halldin
Director of KI PET center 
Phone: +46 8 517 726 78 
Fax: +46 8 517 717 53 
E-Mail to Prof. Christer Halldin Contact  
 



Institute Presentation


The PET-center at Karolinska Institutet is a section of the Department of Clinical Neuroscience. It is a key participant in the Stockholm Brain Institute (SBI) of cognitive neuroscience and serves as a base resource for Psychiatry R&D in the Stockholm region. The center and the two leaders (LF and CH) have been particularly successful in the development of new radioligands for imaging of brain neurotransmission systems. Of all suitable radioligands in the world for this purpose, at least one third have been originally developed here. The list includes widely used ligands such as [11C]raclopride, [11C]SCH23390 and [11C]flumazenil. Following the first quantitative study of receptor binding in the human brain in vivo (1986) the center examined the dopamine hypothesis of schizophrenia and pioneered the use of receptor occupancy to confirm mood of action of CNS-drugs (antipsychotics) and as a tool in drug development. The center has over the years collaborated with at least 20 pharmaceutical companies, of which AstraZeneca currently is a major player. At a behavioural  level, KI was first  to demonstrate a relationship between brain biochemistry and higher brain functions. More recently KI has advanced the image analysis methodology by validating the use of wavelets to obtain parametric images of receptor binding


03 Karolinska Institutet